Abstract 23P
Background
Breast cancer is the second most common cancer in women worldwide and contributes to a significant amount of mortality annually. It also contributes significantly to cancer-related morbidity in Bali especially in Gianyar district where most of the breast cancers are diagnosed at an advanced stage. Therefore, we aimed to evaluate the correlation between the levels of knowledge with the attitude of local-productive age women toward SADARI (breast self-assessment).
Methods
A family-based cross-sectional study was conducted in August 2018 in the Pejeng Kaja village, Ubud, Bali. The level of knowledge such as the definition of breast cancer, risk factors, therapy, prevention and several aspects of SADARI method was examined using a validated questionnaire. All of the data were subsequently recorded into SPSS for analysis.
Results
122 respondents were enrolled in this study with a mean age of 45.65±9.51 years. More than half of the respondents were having at least high school education and 55% know breast cancer. However, 46.7% were known about SADARI. 5 variables were significantly associated with the status of SADARI knowledge namely: level of education, knowledge about breast cancer, breast cancer prevention, and how to perform SADARI as well as the frequency of SADARI performance by respondents (p < 0.05). Risk assessment for each variable showed that all variables had OR > 5 with the biggest OR on the level of education (OR: 7.2; 95%CI: 3.56-14.75).
Conclusions
We conclude that the level of education, knowledge about breast cancer, early symptoms of breast cancer, breast cancer prevention, and how to perform SADARI as well as frequency of SADARI performance influenced the performance rate of SADARI in reproductive women in Pejeng Kaja with low level of education posed the greatest risk of not performing SADARI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract